Epidemiological studies have suggested that adiponectin is associated with the development of insulin resistance and type 2 diabetes. This study first examined the effect of purified anthocyanins, a group of dietary flavonoids, on serum adiponectin in patients with prediabetes and newly diagnosed diabetes. A total of 160 patients with prediabetes (n = 90) or newly diagnosed diabetes (n = 70) were randomly assigned to either the anthocyanins group or the placebo group for 12 weeks of intervention. Serum adiponectin, a set of biomarkers related to glucolipid metabolism, anthropometric parameters, dietary intake and physical activity were measured before and after intervention. Anthocyanins increased serum adiponectin compared with placebo (net change 0.46 µg/mL, 95% CI [0.03, 0.90], p = 0.038) in the subjects with newly diagnosed diabetes. No significant difference in the change in adiponectin was observed between the two groups either in the overall subjects (0.02 µg/mL [− 0.32, 0.36], p = 0.906) or in prediabetes (− 0.35 µg/mL [− 0.85, 0.16], p = 0.174). Anthocyanins also decreased fasting glucose (− 0.5 mmol/L [− 1, − 0.04], p = 0.035) in the subjects with newly diagnosed diabetes, but no such change was observed in those with prediabetes. Anthocyanins supplementation for 12 weeks improved serum adiponectin and fasting glucose in patients with newly diagnosed diabetes, but not in patients with prediabetes. ClinicalTrials.gov, NCT02689765. Registered on 6 February 2016, https://clinicaltrials.gov/ct2/show/NCT02689765 .

中文翻译：

---

花青素在新诊断的糖尿病中增加血清脂联素，但在前驱糖尿病中没有：一项随机对照试验

流行病学研究表明，脂联素与胰岛素抵抗和 2 型糖尿病的发生有关。这项研究首先检查了纯化的花青素（一组膳食类黄酮）对糖尿病前期和新诊断糖尿病患者血清脂联素的影响。共有 160 名糖尿病前期 (n = 90) 或新诊断糖尿病 (n = 70) 的患者被随机分配到花青素组或安慰剂组，进行为期 12 周的干预。在干预前后测量血清脂联素，一组与糖脂代谢、人体测量参数、饮食摄入和身体活动相关的生物标志物。与安慰剂相比，花青素增加了新诊断糖尿病患者的血清脂联素（净变化 0.46 µg/mL，95% CI [0.03, 0.90]，p = 0.038）。在总体受试者（0.02 µg/mL [- 0.32, 0.36], p = 0.906）或糖尿病前期（- 0.35 µg/mL [- 0.85, 0.16]）中，两组之间的脂联素变化没有显着差异, p = 0.174)。花青素还能降低新诊断糖尿病患者的空腹血糖（- 0.5 mmol/L [- 1, - 0.04], p = 0.035），但在糖尿病前期患者中没有观察到这种变化。补充花青素 12 周可改善新诊断糖尿病患者的血清脂联素和空腹血糖，但对前驱糖尿病患者无影响。ClinicalTrials.gov，NCT02689765。2016 年 2 月 6 日注册，https://clinicaltrials.gov/ct2/show/NCT02689765。906）或糖尿病前期（- 0.35 µg/mL [- 0.85, 0.16]，p = 0.174）。花青素还能降低新诊断糖尿病患者的空腹血糖（- 0.5 mmol/L [- 1, - 0.04], p = 0.035），但在糖尿病前期患者中没有观察到这种变化。补充花青素 12 周可改善新诊断糖尿病患者的血清脂联素和空腹血糖，但对前驱糖尿病患者无影响。ClinicalTrials.gov，NCT02689765。2016 年 2 月 6 日注册，https://clinicaltrials.gov/ct2/show/NCT02689765。906）或糖尿病前期（- 0.35 µg/mL [- 0.85, 0.16]，p = 0.174）。花青素还能降低新诊断糖尿病患者的空腹血糖（- 0.5 mmol/L [- 1, - 0.04], p = 0.035），但在糖尿病前期患者中没有观察到这种变化。补充花青素 12 周可改善新诊断糖尿病患者的血清脂联素和空腹血糖，但对前驱糖尿病患者无影响。ClinicalTrials.gov，NCT02689765。2016 年 2 月 6 日注册，https://clinicaltrials.gov/ct2/show/NCT02689765。补充花青素 12 周可改善新诊断糖尿病患者的血清脂联素和空腹血糖，但对前驱糖尿病患者无影响。ClinicalTrials.gov，NCT02689765。2016 年 2 月 6 日注册，https://clinicaltrials.gov/ct2/show/NCT02689765。补充花青素 12 周可改善新诊断糖尿病患者的血清脂联素和空腹血糖，但对前驱糖尿病患者无影响。ClinicalTrials.gov，NCT02689765。2016 年 2 月 6 日注册，https://clinicaltrials.gov/ct2/show/NCT02689765。